GLP-1 Market
LLY $1288.30 ▲ +0.5% NVO $38.29 ▼ -1.0% PFE $29.45 ▼ -1.2% VKTX $25.36 ▲ +1.9% KLRA $13.42 ▲ +2.2% GPCR $21.48 ▼ -0.3% RHHBY $60.22 ▼ -0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

CT-868

CT-868

Company
Carmot Therapeutics, Inc.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Oct 29, 2026

Trial details
  • Completed NCT NCT04973111

    A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

    Not yet reported Carmot Therapeutics, Inc. 32 participants Est. completion 2022-04-22 1 site Stand-alone
    Other conditions: Diabetes
    View official trial listing →
  • Completed NCT NCT05110846

    A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

    Not yet reported Carmot Therapeutics, Inc. 103 participants Est. completion 2023-02-28 5 sites Stand-alone
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Completed NCT NCT05794581

    A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes

    Not yet reported Carmot Therapeutics, Inc. 32 participants Est. completion 2024-04-06 1 site Stand-alone
    Other conditions: Type 1 Diabetes
    View official trial listing →
  • Completed NCT NCT06062069

    A Study of CT-868 in Type 1 Diabetes Mellitus

    Not yet reported Carmot Therapeutics, Inc. 111 participants Est. completion 2025-07-07 22 sites Stand-alone
    Other conditions: Overweight, Obese, Type 1 Diabetes Mellitus
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: CT-868, Acmopatide, RO7795074

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.